Research programme: anti-emesis therapeutics - Paradigm Therapeutics

Drug Profile

Research programme: anti-emesis therapeutics - Paradigm Therapeutics

Alternative Names: SI-162

Latest Information Update: 12 Feb 2008

Price : $50

At a glance

  • Originator Paradigm Therapeutics
  • Developer Takeda Cambridge
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Nausea and vomiting

Most Recent Events

  • 27 Apr 2007 No development reported - Preclinical for Emesis in United Kingdom (unspecified route)
  • 10 Jan 2005 Amedis Pharmaceuticals has been acquired and merged into Paradigm Therapeutics
  • 24 Jun 2004 SI 162 is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top